These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39386736)

  • 21. Radiation drives tertiary lymphoid structures to reshape TME for synergized antitumour immunity.
    Li S; Chen K; Sun Z; Chen M; Pi W; Zhou S; Yang H
    Expert Rev Mol Med; 2024 Oct; 26():e30. PubMed ID: 39438247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrating tertiary lymphoid structure-associated genes into computational models to evaluate prognostication and immune infiltration in pancreatic cancer.
    Ma Y; Li X; Zhang J; Zhao X; Lu Y; Shen G; Wang G; Liu H; Hao J
    J Leukoc Biol; 2024 Sep; 116(3):589-600. PubMed ID: 38484172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tertiary lymphoid structures accompanied by fibrillary matrix morphology impact anti-tumor immunity in basal cell carcinomas.
    Byers C; Gill M; Kurtansky NR; Alessi-Fox C; Harman M; Cordova M; Gonzalez S; Guitera P; Rotemberg V; Marghoob A; Chen CJ; Dy J; Kose K; Rajadhyaksha M; Sahu A
    Front Med (Lausanne); 2022; 9():981074. PubMed ID: 36388913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multi-omics profiling and experimental verification of tertiary lymphoid structure-related genes: molecular subgroups, immune infiltration, and prognostic implications in lung adenocarcinoma.
    Wu S; Pan J; Pan Q; Zeng L; Liang R; Li Y
    Front Immunol; 2024; 15():1453220. PubMed ID: 39364403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy.
    Li X; Wan Z; Liu X; Ou K; Yang L
    Med Oncol; 2022 Jan; 39(4):43. PubMed ID: 35092511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.
    Lutz ER; Wu AA; Bigelow E; Sharma R; Mo G; Soares K; Solt S; Dorman A; Wamwea A; Yager A; Laheru D; Wolfgang CL; Wang J; Hruban RH; Anders RA; Jaffee EM; Zheng L
    Cancer Immunol Res; 2014 Jul; 2(7):616-31. PubMed ID: 24942756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies.
    Senturk ZN; Akdag I; Deniz B; Sayi-Yazgan A
    Front Immunol; 2023; 14():1152551. PubMed ID: 37033931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma.
    Liang H; Zhang Z; Guan Z; Zheng S; Lou J; Liu W; Cai Q; Si Y
    Front Immunol; 2023; 14():1096220. PubMed ID: 36776859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.
    Zhang S; Yuan L; Danilova L; Mo G; Zhu Q; Deshpande A; Bell ATF; Elisseeff J; Popel AS; Anders RA; Jaffee EM; Yarchoan M; Fertig EJ; Kagohara LT
    Genome Med; 2023 Sep; 15(1):72. PubMed ID: 37723590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma.
    Xu W; Ma C; Liu W; Anwaier A; Tian X; Shi G; Qu Y; Wei S; Zhang H; Ye D
    Cancer Immunol Immunother; 2022 Aug; 71(8):1923-1935. PubMed ID: 35043231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
    Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
    EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphocyte Function in Tertiary Lymphoid Structures Predicts Hepatocellular Carcinoma Outcome.
    Li J; Xu H; Han J; Sun P; Zhang X; Wang H; Bian T; Xu Q; Ji J; Huang J
    Lab Invest; 2024 Nov; 104(11):102144. PubMed ID: 39343010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.
    Liudahl SM; Betts CB; Sivagnanam S; Morales-Oyarvide V; da Silva A; Yuan C; Hwang S; Grossblatt-Wait A; Leis KR; Larson W; Lavoie MB; Robinson P; Dias Costa A; Väyrynen SA; Clancy TE; Rubinson DA; Link J; Keith D; Horton W; Tempero MA; Vonderheide RH; Jaffee EM; Sheppard B; Goecks J; Sears RC; Park BS; Mori M; Nowak JA; Wolpin BM; Coussens LM
    Cancer Discov; 2021 Aug; 11(8):2014-2031. PubMed ID: 33727309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma.
    Merali N; Jessel MD; Arbe-Barnes EH; Ruby Lee WY; Gismondi M; Chouari T; O'Brien JW; Patel B; Osei-Bordom D; Rockall TA; Sivakumar S; Annels N; Frampton AE
    HPB (Oxford); 2024 Jul; 26(7):873-894. PubMed ID: 38729813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
    Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mapping the complexity and diversity of tertiary lymphoid structures in primary and peritoneal metastatic gastric cancer.
    Groen-van Schooten TS; Franco Fernandez R; van Grieken NCT; Bos EN; Seidel J; Saris J; Martínez-Ciarpaglini C; Fleitas TC; Thommen DS; de Gruijl TD; Grootjans J; Derks S
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38955417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiplexed Imaging Mass Cytometry Analysis Characterizes the Vascular Niche in Pancreatic Cancer.
    Sussman JH; Kim N; Kemp SB; Traum D; Katsuda T; Kahn BM; Xu J; Kim IK; Eskandarian C; Delman D; Beatty GL; Kaestner KH; Simpson AL; Stanger BZ
    Cancer Res; 2024 Jul; 84(14):2364-2376. PubMed ID: 38695869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
    Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
    Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling.
    Johansson-Percival A; Ganss R
    Front Immunol; 2021; 12():674375. PubMed ID: 34122434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.